(1) Background: Minimally invasive surgery (MIS) represents a feasible approach in early-stage ovarian cancer, while this question is still unsolved for advanced and recurrent disease. (2) Methods: In this retrospective, multicenter study, we present a series of 21 patients who underwent MIS for primitive or recurrent epithelial ovarian cancer (EOC) with bulky nodal metastasis and discuss surgical technique and outcomes in relation to the current literature. (3) Results: Complete cytoreduction at primary debulking surgery was obtained in 86% of cases. No complication occurred in our patients intraoperatively and only 11.1% of our patients experienced grade 2 and 3 postoperative complications. Notably, all the patients with isolated lymph nodal recurrence (ILNR) were successfully treated with a minimally invasive approach with no intra- or postoperative complications. (4) Conclusions: The results of our study are consistent with those reported in the literature, demonstrating that MIS may represent a safe approach in advanced and recurrent EOC with nodal metastasis if performed on selected patients by expert surgeons with an adequate setting and appropriate technique.
（1）背景：微创手术（MIS）是早期卵巢癌的可行治疗手段，但对于晚期及复发性病例，其适用性仍待明确。（2）方法：本项回顾性多中心研究纳入21例接受MIS治疗的原发性或复发性上皮性卵巢癌（EOC）伴大体积淋巴结转移患者，结合现有文献探讨手术技术及临床结局。（3）结果：初次肿瘤细胞减灭术实现完全切除率达86%。术中无并发症发生，仅11.1%患者出现2-3级术后并发症。值得注意的是，所有孤立性淋巴结复发（ILNR）患者均通过微创手术成功治疗，且无术中或术后并发症。（4）结论：本研究结果与文献报道一致，表明对于经严格筛选的淋巴结转移晚期及复发性EOC患者，由经验丰富的外科医生在适宜条件下采用恰当技术实施MIS，可成为安全有效的治疗选择。
肿瘤(癌症)患者之家